Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Trading Floor Community IconFrom the Trading Floor:
Beam Therapeutics Inc Logo

ARKG Holdings of Beam Therapeutics (BEAM) - Updated Daily

Lock IconJoin Premium Plan
The Bucket Report Icon
The Bucket ReportSubscribe to get all the important numbers from the financial markets delivered to your inbox every trading day ๐Ÿ“ซ
Date
Direction
Shares
Fund Weight
Fund
January 20, 2022BUY22.800k0.0375%ARKG
January 18, 2022BUY75.791k0.1117%ARKG
January 5, 2022BUY18.600k0.0263%ARKG
January 3, 2022BUY14.400k0.0229%ARKG
December 30, 2021BUY5.200k0.0084%ARKG

Key Statistics

๐Ÿ•ต๐ŸผFound In๐ŸทLast Price
ARKKARKG$56.78
โš–๏ธWeighting๐ŸงขMarket Cap
3.62%$3.90b
๐Ÿ‹๐Ÿฟโ€โ™‚๏ธWeight Rank In ARKG๐ŸงฎPrice to Sales
975.27
๐Ÿ‹๏ธโ€โ™€๏ธWeight Rank Across All Funds๐ŸŒCountry
15๐Ÿ‡บ๐Ÿ‡ธUnited States
๐Ÿ’ณARK Estimated Cost Average๐ŸŽซARK Ownership Percent
$83.563.14%
Description
Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Website
beamtx.com

Research Notes and Commentary for BEAM